Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

Cherie T. Ng; J. Pablo Jaworski; Pushpa Jayaraman; William F. Sutton; Patrick Delio; Larene Kuller; David Anderson; Gary Landucci; Barbra A. Richardson; Dennis R. Burton; Donald N. Forthal; Nancy L. Haigwood

doi:10.1038/nm.2233

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

Cherie T. Ng
, J. Pablo Jaworski
, Pushpa Jayaraman
, William F. Sutton
, Patrick Delio
, Larene Kuller
, David Anderson
, Gary Landucci
, Barbra A. Richardson
, Dennis R. Burton
, Donald N. Forthal
, Nancy L. Haigwood

Oregon National Primate Research Center

Research output: Contribution to journal › Article › peer-review

138 Scopus citations

Abstract

Maternal HIV-1-specific antibodies are efficiently transferred to newborns, but their role in disease control is unknown. We administered neutralizing IgG, including the human neutralizing monoclonal IgG1b12, at levels insufficient to block infection, to six newborn macaques before oral challenge with simian-HIV strain SF162P3 (SHIV_SF162P3). All of the macaques rapidly developed neutralizing antibodies and had significantly reduced plasma viremia for six months. These studies support the use of neutralizing antibodies in enhancing B cell responses and viral control in perinatal settings.

Original language	English (US)
Pages (from-to)	1117-1119
Number of pages	3
Journal	Nature medicine
Volume	16
Issue number	10
DOIs	https://doi.org/10.1038/nm.2233
State	Published - Oct 2010

Funding

We would like to thank Z. Brower for technical support, D. Morris and K. Filer for manuscript preparation, M.L. Marthas and K.K.A. Van Rompay for advice on subcutaneous dosing of IgG and oral inoculation of infants, J. Overbaugh (Fred Hutchinson Cancer Research Center) for the Env-deleted viral backbone plasmid Q23ΔEnv, S. Barnett and I. Srinivasan (Novartis) for recombinant gp120-SF162 and V. Planelles (University of Utah) for the plasmid pEMC*. M. Piatak and J.D. Lifson (Science Applications International Corporation) kindly provided RNA standards and advice on real-time PCR. SHIVSF162P3 was supplied by N. Miller (US National Institutes of Health Division of AIDS) and R. Pal (Advanced Bioscience Labs). TZM-bl were supplied by the US National Institutes of Health AIDS Research Reference Reagent Program. This study was supported by grants from the US National Institutes of Health R01HD038653 (N.L.H.), R01AI33292 (D.R.B.) and R01AI052039 (D.N.F.) and from the Elizabeth Glaser Pediatric AIDS Foundation (N.L.H.).

Funders	Funder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health	R01AI33292, R01HD038653
National Institute of Allergy and Infectious Diseases	R01AI052039
Elizabeth Glaser Pediatric AIDS Foundation

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/nm.2233

Cite this

@article{8b1e5c4498584994a6627d0dc9612a44,

title = "Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques",

abstract = "Maternal HIV-1-specific antibodies are efficiently transferred to newborns, but their role in disease control is unknown. We administered neutralizing IgG, including the human neutralizing monoclonal IgG1b12, at levels insufficient to block infection, to six newborn macaques before oral challenge with simian-HIV strain SF162P3 (SHIVSF162P3). All of the macaques rapidly developed neutralizing antibodies and had significantly reduced plasma viremia for six months. These studies support the use of neutralizing antibodies in enhancing B cell responses and viral control in perinatal settings.",

author = "Ng, \{Cherie T.\} and Jaworski, \{J. Pablo\} and Pushpa Jayaraman and Sutton, \{William F.\} and Patrick Delio and Larene Kuller and David Anderson and Gary Landucci and Richardson, \{Barbra A.\} and Burton, \{Dennis R.\} and Forthal, \{Donald N.\} and Haigwood, \{Nancy L.\}",

note = "Funding Information: We would like to thank Z. Brower for technical support, D. Morris and K. Filer for manuscript preparation, M.L. Marthas and K.K.A. Van Rompay for advice on subcutaneous dosing of IgG and oral inoculation of infants, J. Overbaugh (Fred Hutchinson Cancer Research Center) for the Env-deleted viral backbone plasmid Q23ΔEnv, S. Barnett and I. Srinivasan (Novartis) for recombinant gp120-SF162 and V. Planelles (University of Utah) for the plasmid pEMC*. M. Piatak and J.D. Lifson (Science Applications International Corporation) kindly provided RNA standards and advice on real-time PCR. SHIVSF162P3 was supplied by N. Miller (US National Institutes of Health Division of AIDS) and R. Pal (Advanced Bioscience Labs). TZM-bl were supplied by the US National Institutes of Health AIDS Research Reference Reagent Program. This study was supported by grants from the US National Institutes of Health R01HD038653 (N.L.H.), R01AI33292 (D.R.B.) and R01AI052039 (D.N.F.) and from the Elizabeth Glaser Pediatric AIDS Foundation (N.L.H.).",

year = "2010",

month = oct,

doi = "10.1038/nm.2233",

language = "English (US)",

volume = "16",

pages = "1117--1119",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "10",

}

TY - JOUR

T1 - Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

AU - Ng, Cherie T.

AU - Jaworski, J. Pablo

AU - Jayaraman, Pushpa

AU - Sutton, William F.

AU - Delio, Patrick

AU - Kuller, Larene

AU - Anderson, David

AU - Landucci, Gary

AU - Richardson, Barbra A.

AU - Burton, Dennis R.

AU - Forthal, Donald N.

AU - Haigwood, Nancy L.

N1 - Funding Information: We would like to thank Z. Brower for technical support, D. Morris and K. Filer for manuscript preparation, M.L. Marthas and K.K.A. Van Rompay for advice on subcutaneous dosing of IgG and oral inoculation of infants, J. Overbaugh (Fred Hutchinson Cancer Research Center) for the Env-deleted viral backbone plasmid Q23ΔEnv, S. Barnett and I. Srinivasan (Novartis) for recombinant gp120-SF162 and V. Planelles (University of Utah) for the plasmid pEMC*. M. Piatak and J.D. Lifson (Science Applications International Corporation) kindly provided RNA standards and advice on real-time PCR. SHIVSF162P3 was supplied by N. Miller (US National Institutes of Health Division of AIDS) and R. Pal (Advanced Bioscience Labs). TZM-bl were supplied by the US National Institutes of Health AIDS Research Reference Reagent Program. This study was supported by grants from the US National Institutes of Health R01HD038653 (N.L.H.), R01AI33292 (D.R.B.) and R01AI052039 (D.N.F.) and from the Elizabeth Glaser Pediatric AIDS Foundation (N.L.H.).

PY - 2010/10

Y1 - 2010/10

N2 - Maternal HIV-1-specific antibodies are efficiently transferred to newborns, but their role in disease control is unknown. We administered neutralizing IgG, including the human neutralizing monoclonal IgG1b12, at levels insufficient to block infection, to six newborn macaques before oral challenge with simian-HIV strain SF162P3 (SHIVSF162P3). All of the macaques rapidly developed neutralizing antibodies and had significantly reduced plasma viremia for six months. These studies support the use of neutralizing antibodies in enhancing B cell responses and viral control in perinatal settings.

AB - Maternal HIV-1-specific antibodies are efficiently transferred to newborns, but their role in disease control is unknown. We administered neutralizing IgG, including the human neutralizing monoclonal IgG1b12, at levels insufficient to block infection, to six newborn macaques before oral challenge with simian-HIV strain SF162P3 (SHIVSF162P3). All of the macaques rapidly developed neutralizing antibodies and had significantly reduced plasma viremia for six months. These studies support the use of neutralizing antibodies in enhancing B cell responses and viral control in perinatal settings.

UR - https://www.scopus.com/pages/publications/77957820631

UR - https://www.scopus.com/pages/publications/77957820631#tab=citedBy

U2 - 10.1038/nm.2233

DO - 10.1038/nm.2233

M3 - Article

C2 - 20890292

AN - SCOPUS:77957820631

SN - 1078-8956

VL - 16

SP - 1117

EP - 1119

JO - Nature medicine

JF - Nature medicine

IS - 10

ER -

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this